Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.47 |
| ▸ | EZH2 | Q15910 | 9/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5653991 | 0.91 | GLA (0.52) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5648442 | 0.90 | GLA (0.55) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5649610 | 0.89 | L3MBTL1 (0.53) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5649773 | 0.88 | MEN1 (0.52) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5653084 | 0.85 | KMT2A (0.48) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5650388 | 0.85 | MEN1 (0.45) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5652118 | 0.85 | EZH2 (0.53) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5649008 | 0.83 | EZH2 (0.49) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5649693 | 0.82 | GLA (0.57) | KMT2AMEN1L3MBTL1GLAEZH2 | |
| SCHEMBL5652809 | 0.81 | MEN1 (0.53) | KMT2AMEN1L3MBTL1GLAEZH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220769-B2 | Azolylbenzamides and analogues and their use for treating osteoporosis | NIKEM RESEARCH S.R.L. (IT) | 2007-05-22 | — | — | US | disclosed |
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | 3-V BIOSCIENCES, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038095-A1 | Azolylbenzamides and analogues and their use for treating osteoporosis | NR0B2, NR0B1, NCOR1 | KMT2A 439/4885MEN1 3545/4885L3MBTL1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.